Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIPARP | Q7Z3E1 | 20/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.36 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.36 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26915101 | 1.00 | TIPARP (0.36) | TIPARPPARP1CYP2C9PARP14PARP16 | |
| SCHEMBL21520955 | 0.88 | TIPARP (0.41) | TIPARPPARP1CYP2C9PARP14PARP16 | |
| SCHEMBL21521226 | 0.88 | TIPARP (0.41) | TIPARPPARP1CYP2C9PARP14PARP16 | |
| SCHEMBL30565547 | 0.88 | TIPARP (0.34) | TIPARPPARP1CYP2C9PARP14PARP16 | |
| SCHEMBL30286360 | 0.86 | TIPARP (0.36) | TIPARPPARP1CYP2C9PARP14PARP16 | |
| SCHEMBL26915049 | 0.86 | TIPARP (0.33) | TIPARPPARP1CYP2C9PARP14PARP16 | |
| SCHEMBL26120933 | 0.86 | TIPARP (0.34) | TIPARPPARP1CYP2C9PARP14PARP16 | |
| SCHEMBL26120938 | 0.86 | TIPARP (0.34) | TIPARPPARP1CYP2C9PARP14PARP16 | |
| SCHEMBL21521662 | 0.86 | TIPARP (0.41) | TIPARPPARP1CYP2C9PARP14PARP16 | |
| SCHEMBL21521661 | 0.86 | TIPARP (0.41) | TIPARPPARP1CYP2C9PARP14PARP16 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-05-23 | — | — | US | disclosed |
| EP-4289845-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WEE1, WEE2 | TIPARP 23/4885PARP1 14/4885CYP2C9 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.